Polymorphism COX-1 to Platelet Aggregation in Coronary Heart Disease Patients: Polimorfisme COX-1 terhadap Agregasi Platelet pada Pasien Penyakit Jantung Koroner

Charliandri Saputra Wahab; J. Nugroho Eko  Putranto; Ike Dhiah Rochmawati

doi:10.53342/pharmasci.v6i1.203

Authors

Charliandri Saputra Wahab Universitas Surabaya
J. Nugroho Eko Putranto Rumah Sakit Umum Dr. Soetomo
Ike Dhiah Rochmawati Universitas Surabaya

DOI:

https://doi.org/10.53342/pharmasci.v6i1.203

Keywords:

Platelet aggregation, Coronary artery disease, COX-1 polymorphism

Abstract

The Genetic Polymorphism of COX-1 (Cyclooxygenase 1) is one of the factors causing variations in the
response to platelet aggregation. These variations can cause Coronary Artery Disease (CAD) in patients
with Coronary Heart Disease. This cross-sectional research was conducted at Sidoarjo General Hospital in
East Java from November to December 20217. This observational research was used for checking the COX1 polymorphism with Polymerase Chain Reaction (PCR) and platelet aggregation with the Light
Transmittance Aggregonetry (LTA) method for measuring platelet aggregation. Majority of patients involved
in this research were 45-64 years (93.34%), men (53.33%), and overweight (80.00%). From 30 patients
involved in this study, 13.33% showed homozygote (wild type) COX-1 polymorphisms and 86.67% showed
heterozygote COX-1 polymorphisms. The majority patients with homozygot and heterozygot polymorphisms
showed normo aggregation with 75.00% and 84.62%, subsequently. Statistical analysis with Mann Whitney
showed that there is no relationship between COX-1 polymorphisms and platelet aggregation (p= 0.423).
Further research should be conducted to explore other factors that contribute to platelet aggregation.